Mason Health (02415.HK): It is expected that the mid-term net profit will decrease but the gross margin will increase. The company will maintain profitability.

Gelonghui Finance · Aug 26 09:10

Gelonghui announced on August 26th that for the six months ending June 30, 2024 (the 'reporting period'), it is expected that the net profit for the reporting period will decrease to no more than 0.5 million yuan from 11.9 million yuan for the six months ending June 30, 2023 (the 'corresponding period'), mainly due to (i) the temporary delay in the recognition of revenue from the precision omni-channel marketing solution and real-world clinical research solution projects, which were delayed due to the delayed implementation of the projects, resulting in a decrease in the group's revenue for the reporting period compared to the corresponding period; (ii) the fair value gain of approximately 12.8 million yuan on the convertible redeemable preferred shares in the corresponding period; and (iii) an increase in administrative expenses due to the grant of share-based incentives under the company's share incentive plan. Despite this, the company expects to remain profitable, and the gross margin for the reporting period is expected to be higher than that of the corresponding period. The company is confident in its strategic direction and will continue to optimize its operations to create long-term value for shareholders.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

梅斯健康(02415.HK)：预计中期纯利减少但毛利率提升 公司将保持盈利

Mason Health (02415.HK): It is expected that the mid-term net profit will decrease but the gross margin will increase. The company will maintain profitability.

Risk Disclaimer

Statement

梅斯健康(02415.HK)：预计中期纯利减少但毛利率提升公司将保持盈利